LSK Global PS Conducts Phase 3 Clinical Trial of Sinovac COVID-19 Vaccine in China

[Asia Economy Reporter Cho Hyun-ui] LSK Global Pharma Services (hereinafter LSK Global PS), a domestic contract research organization (CRO), announced on the 1st that it will conduct the Phase 3 clinical trial of the novel coronavirus disease (COVID-19) vaccine candidate 'PiCoVac' developed by China's Sinovac in Bangladesh.

This clinical trial will be conducted on approximately 4,200 healthcare workers at seven hospitals in the Dhaka area of Bangladesh. The hospitals where the trial is conducted are primarily responsible for treating COVID-19 patients, so the risk of infection for healthcare workers is high.

The clinical trial will be conducted in a non-face-to-face manner due to the spread of COVID-19. Tests, informed consent, and vaccine administration for trial participation will be conducted face-to-face, while monitoring such as health status reporting will be done online.

Lee Young-jak, CEO of LSK Global PS, said, "As we have prepared for non-face-to-face clinical trials for several years in response to changes in the clinical trial environment, we will successfully complete this trial as well."

This content was produced with the assistance of AI translation services.